Free Trial

Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold by StockNews.com

Galectin Therapeutics logo with Medical background

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) was upgraded by investment analysts at StockNews.com from a "sell" rating to a "hold" rating in a report released on Tuesday.

Separately, HC Wainwright restated a "buy" rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a report on Friday, August 16th.

Read Our Latest Report on Galectin Therapeutics

Galectin Therapeutics Stock Performance

Shares of GALT traded down $0.03 during trading hours on Tuesday, reaching $2.60. The stock had a trading volume of 109,152 shares, compared to its average volume of 145,580. Galectin Therapeutics has a 12 month low of $1.55 and a 12 month high of $4.27. The stock has a market capitalization of $161.58 million, a PE ratio of -3.55 and a beta of 0.61. The company's 50-day moving average is $2.54 and its two-hundred day moving average is $2.73.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.04). Equities analysts anticipate that Galectin Therapeutics will post -0.79 earnings per share for the current fiscal year.

Institutional Trading of Galectin Therapeutics

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Galectin Therapeutics by 2.0% during the 1st quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company's stock worth $4,732,000 after acquiring an additional 38,037 shares during the period. Commonwealth Equity Services LLC boosted its position in shares of Galectin Therapeutics by 317.6% during the 2nd quarter. Commonwealth Equity Services LLC now owns 483,351 shares of the company's stock worth $1,092,000 after purchasing an additional 367,610 shares in the last quarter. Wealthspire Advisors LLC boosted its position in shares of Galectin Therapeutics by 116.7% during the 1st quarter. Wealthspire Advisors LLC now owns 398,374 shares of the company's stock worth $952,000 after purchasing an additional 214,512 shares in the last quarter. Sanctuary Advisors LLC bought a new position in shares of Galectin Therapeutics during the 2nd quarter worth about $227,000. Finally, Squarepoint Ops LLC boosted its position in shares of Galectin Therapeutics by 75.4% during the 2nd quarter. Squarepoint Ops LLC now owns 84,074 shares of the company's stock worth $190,000 after purchasing an additional 36,139 shares in the last quarter. 11.68% of the stock is currently owned by institutional investors and hedge funds.

About Galectin Therapeutics

(Get Free Report)

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.

Featured Stories

→ 625,000% Gain (From Crypto Swap Profits) (Ad)

Should you invest $1,000 in Galectin Therapeutics right now?

Before you consider Galectin Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.

While Galectin Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines